SureTrader Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: Seel
Search This Board:
Last Post: 4/27/2016 1:27:29 AM - Followers: 156 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
Wiki
SureTrader
IDRA News: Notice of Effectiveness (effect) 04/27/2016 06:01:31 AM
IDRA News: Proxy Statement (definitive) (def 14a) 04/25/2016 04:11:26 PM
IDRA News: Idera Presents Preclinical Data Demonstrating Enhanced Systemic Anti-Tumor Activity from Combination Treatment with Intra-tum... 04/19/2016 07:30:00 AM
IDRA News: Idera to Present at the 15th Annual Needham Healthcare Conference 04/11/2016 10:30:00 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 04/05/2016 06:01:58 PM
PostSubject
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#2389   Pay attention as we are near a historic Citrati 04/27/16 01:27:29 AM
#2388   I can definitely stay in and wait for rivervalley 04/22/16 02:00:59 PM
#2387   ASCO conference is in 6 weeks. IDRA not Seel 04/22/16 12:53:01 PM
#2386   This is what happens when you go to rivervalley 04/22/16 11:06:32 AM
#2385   Yeah, I hear you. Citrati 04/21/16 11:12:43 AM
#2384   can't quite wrap my head around this one C.... TheHound 04/21/16 10:26:10 AM
#2383   IDRA trying to make a move. Hope this rivervalley 04/13/16 03:50:11 PM
#2382   Weee! Finally got some $1.80's. billmick11 04/12/16 02:28:00 PM
#2381   Yes it does! And its due. I'm ready.$$$. Seel 04/11/16 07:37:36 PM
#2380   See how long it takes to make another run. Citrati 04/11/16 06:40:22 PM
#2379   a pass and hold of the 2.20 range rivervalley 04/04/16 11:20:08 AM
#2378   Taking off! theycallmejg15 04/04/16 10:29:16 AM
#2377   Alright IDRA lets hold the uptrend line and Citrati 03/29/16 01:32:45 PM
#2376   Let's see if this resumes back up next rivervalley 03/26/16 12:46:10 PM
#2375   ;-) threw everything at CLF yesterday at the TheHound 03/24/16 01:28:29 PM
#2374   Were you happy with 1.85 or were you Citrati 03/24/16 11:04:22 AM
#2373   here comes our sweet spot! ;-) TheHound 03/23/16 10:48:44 AM
#2371   Exactly! Got $2.14 today - feel billmick11 03/18/16 04:23:03 PM
#2370   not sure but this is my 3rd $1.80 TheHound 03/18/16 12:59:32 PM
#2369   I've been in for a few k since noretreat 03/18/16 12:33:49 PM
#2368   Guess everyone is on vacation and not checking Citrati 03/18/16 12:26:57 PM
#2367   Seems like a pretty good sign when a Citrati 03/18/16 09:35:41 AM
#2366   IMO-2125 Abstract for AACR Meeting. DTheMan 03/17/16 08:00:52 AM
#2365   Congrats on your position. You probably know that Citrati 03/14/16 10:18:09 AM
#2364   Hi Citrati, I have been following IDRA for DTheMan 03/14/16 10:14:40 AM
#2363   agree. solid. TheHound 03/14/16 10:14:13 AM
#2362   Early stage bios "Always" need funding. To have Citrati 03/14/16 10:01:40 AM
#2361   I just read the filed of the S-3 DTheMan 03/14/16 09:16:21 AM
#2360   Jumping back in 1.83 Soon Cbdpotential 03/12/16 02:39:11 AM
#2359   Agree that in the recent range it should rivervalley 03/11/16 04:22:17 PM
#2358   this one is a comparatively safe trade at TheHound 03/11/16 03:34:55 PM
#2357   It did a lot worse than IBB or rivervalley 03/11/16 10:12:34 AM
#2356   back in my portfolio for now :-) TheHound 03/11/16 08:22:45 AM
#2355   Back in the channel for now. Citrati 03/10/16 11:19:09 PM
#2354   http://www.thestreet.com/story/13489914/1/idera-pharmaceuticals-reports-fourth-q TheHound 03/10/16 09:14:09 AM
#2353   I'm not sure I follow your logic, but TheHound 03/09/16 05:01:57 PM
#2352   Let's hope it is an easy trade. I've rivervalley 03/09/16 05:00:11 PM
#2351   Thanks! I feel great :-) easy trade. TheHound 03/09/16 04:52:44 PM
#2350   That certainly isn't the only thing to look rivervalley 03/09/16 04:50:44 PM
#2349   30 day MA. No surprise at all. Nailed it. TheHound 03/09/16 03:55:54 PM
#2348   Have to say I'm a little surprised this rivervalley 03/09/16 03:15:58 PM
#2347   Enough cash until Q3/2017...things are progressing! Took out Canoepaddler 03/07/16 07:18:36 PM
#2346   Idra to present at two conferences in March: http://ir.iderapharma.com/phoenix. Canoepaddler 03/03/16 02:14:52 PM
#2345   Nice to see so many bio's green today! rivervalley 03/02/16 03:54:35 PM
#2344   :-) Citrati 03/02/16 03:03:09 PM
#2343   Nice start here early. RSI over 50 now. rivervalley 03/02/16 10:10:14 AM
#2342   Looking great ! :-D Cbdpotential 03/02/16 12:01:53 AM
#2341   Looking good. Have been accumulating. Canoepaddler 03/01/16 06:55:32 PM
#2340   This one did better today than any of rivervalley 03/01/16 04:32:20 PM
#2339   moving on up. let's go IDRA! TheHound 03/01/16 12:27:20 PM
PostSubject